GlobeNewswire Inc.··NaGrace Therapeutics' GTx-104 Meets Primary Endpoint in Pivotal aSAH Trial
Grace Therapeutics reports STRIVE-ON Phase 3 trial success for GTx-104, reducing hypotension and improving outcomes in aneurysmal subarachnoid hemorrhage patients versus oral nimodipine.
GRCEclinical trial resultsGTx-104